ClinicalTrials.Veeva

Menu
O

Orlando Clinical Research Center | Orlando, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BMS-986177
Daclatasvir
BMS-650032
BMS-790052
Ferric Pyrophosphate Citrate
Surufatinib
CIN-107
SSP-004184
Tirzepatide
Palbociclib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

19 of 259 total trials

A Clinical Study of MK-1084 in Participants With Renal Impairment (MK-1084-010)

The goal of this study is to learn what happens to MK-1084 levels in a person's body over time. Researchers will measure what happens to MK-1084 leve...

Enrolling
Renal Impairment
Healthy
Drug: MK-1084

The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic functi...

Enrolling
Liver Diseases
Drug: Etavopivat

The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when gi...

Enrolling
Healthy
Liver Dysfunction
Drug: Lepodisiran

The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemabrutinib (MK-1026) following a single oral dose of nemtabrutinib in p...

Enrolling
Hepatic Impairment (HI)
Drug: Nemtabrutinib

The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered t...

Enrolling
Healthy
Hepatic Insufficiency
Drug: Olomorasib

The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's proc...

Enrolling
Hepatic Impairment
Healthy
Drug: Palovarotene

The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in hea...

Enrolling
Hepatic Impairment
Healthy Volunteers
Drug: Repotrectinib

The purpose of this study is to assess the effect of severe renal impairment (RI) and end-stage renal disease (ESRD) with intermittent hemodialysis (...

Enrolling
Renal Impairment
Healthy Volunteers
Drug: BMS-986278

The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healt...

Enrolling
End-Stage Kidney Disease
Healthy Participants
Drug: Prednisone
Drug: Fludrocortisone acetate

This is a phase 1, open-label, single-dose, parallel-cohort study to determine the pharmacokinetics (PK) of divarasib in healthy participants and par...

Enrolling
Hepatic Impairment
Drug: Divarasib

This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with moderate hepatic impairment and subj...

Enrolling
COVID-19
Drug: ALG-097558

This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with severe renal impairment and subjects...

Enrolling
COVID 19
Drug: ALG-097558

The purpose of this study is to measure the effect of HI on the PK, safety, and tolerability of a single dose of mavorixafor compared to matched heal...

Enrolling
Hepatic Insufficiency
Drug: Mavorixafor

The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal r...

Active, not recruiting
Renal Impairment
Drug: VIR-2218

This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function com...

Enrolling
Healthy Volunteer
Hepatic Impairment (HI)
Drug: varegacestat

This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer pa...

Enrolling
Hepatic Impairment
Drug: ESK-001

This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer pa...

Enrolling
Renal Impairment
Drug: ESK-001

The purposes of this study are to determine:* The pharmacokinetics (the amount of study drug in your blood and how long it takes the body to get rid...

Enrolling
Hepatic Impairment
Healthy
Drug: Mirdametinib (MEK Inhibitor)

The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic...

Enrolling
Hepatic Impairment
Healthy Volunteers
Drug: BMS-986369

Trial sponsors

Bristol-Myers Squibb (BMS) logo
Lilly logo
Pfizer logo
Gilead Sciences logo
Merck Sharp & Dohme (MSD) logo
Novartis logo
Janssen (J&J Innovative Medicine) logo
Bayer logo
Boehringer Ingelheim logo
Eisai logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems